Work Here?
About Editas Medicine
Industries
Biotechnology
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2013
Overview
Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and bringing them to market. Editas Medicine aims to create effective and lasting therapies that can enhance the quality of life for patients suffering from serious health conditions. Unlike many competitors, Editas Medicine has a diverse pipeline of experimental medicines and actively shares clinical data to keep stakeholders informed. Their goal is to provide transformative treatments for patients worldwide.
Simplify's Take
What believers are saying
- In-vivo gene editing shows promise in treating blood-forming stem cells and liver diseases.
- $50+ million financing supports strategic pivot towards innovative gene editing projects.
- Collaboration with Genevant accelerates development of novel gene editing treatments.
What critics are saying
- Executive turnover may affect financial strategy and investor confidence.
- 65% workforce reduction could delay development timelines and impact morale.
- Failure to secure sickle cell partner indicates challenges in collaboration and market positioning.
What makes Editas Medicine unique
- Editas Medicine focuses on in-vivo gene editing for stem cells and liver diseases.
- The company leverages CRISPR technology for precise DNA editing in therapeutic development.
- Editas collaborates with Genevant Sciences to enhance mRNA-LNP gene editing therapeutics.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1146M
Above
Industry Average
Funded Over
5 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Tuition Reimbursement
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Plan
Wellness Program
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
â 7%1 year growth
â 12%2 year growth
â 8%Amy Parsion Senior Vice President of Finance Amy Parison Appointed CFOErick J. Lucera to Step Down as CFO to pursue another opportunitySenior Vice President of Finance Amy Parison Appointed CFOCAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer.âWe are thrilled to promote Amy to the executive leadership team as our new CFO
Erick J. Lucera Erick J. Lucera, Chief Financial Officer (CFO) of Dyne Therapeutics- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera, as chief financial officer (CFO) of Dyne, effective March 31, 2025. Mr
Following Lucera's departure, Editas has appointed Amy Parison, the current Senior Vice President of Finance, as the new Senior Vice President, Chief Financial Officer, and Treasurer.
Editas Medicine (NASDAQ: EDIT) has announced it will release its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, through a press release and SEC filings.
Editas is shifting focus to developing in-vivo treatments that edit stem cells inside the human body after recent pre-clinical data showed promise in blood-forming stem cells and the liver, and plans to share data and development timelines in the first quarter of 2025.
There are no jobs for Editas Medicine right now.
Find jobs on Simplify and start your career today
About Editas Medicine
Industries
Biotechnology
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2013
There are no jobs for Editas Medicine right now.
Find jobs on Simplify and start your career today